Partnerships vs FDA, page-3

First 3 Last

Share
Profile

Follow
Bigdaddio

146 Posts.

16

21/01/21

07:11

Post #: 50325649
Share

Originally posted by bedger: ↑

A lot of investors still seem hoping for an EUA in C-19 ARDS, whilst even the company was not optimistic enough to encourage that hope. CHF, the company will meet with the FDA to discuss a potential pathway to approval on the basis of the results on the MACE. But even if the primary endpoint had been met FDA approval was always likely to involve a further (partnered?) trial for FDA approval be it conditional or otherwise. GVHD we may yet gain FDA approval (with a conditional RCT) via an accelerated BLA. CLBP may yet prove successful, but not necessarily mean automatic FDA approval, but will certainly help in that end.

Whilst ultimately FDA approval is crucial, partnerships are the real underlying driver of commerciality in most young bio-tech companies. Fate Therapeutics, another US stem-cell company announced a $100 million up front equity and $3 billion in milestone payments with Johnson and Johnson. Fate has had no regulatory approvals, some recent trial success admittedly, but risen from $20 to nearly $120 since the April 2020 announcement of the partnership.

Conversely another Australian stem-call company that gained FDA approval in one of its ancillary products (a collagen scaffold) last week has risen from $0.46 to a paltry $0.505 as of today. Whilst it has a Johnson and Johnson trial in progress it has no formal partnership in place. FDA approval is not always the share price driver.

Partnerships are more commonly the real drivers of pre-commercial bio-tech share price and MSB has three existing small partnerships of course and hopefully a fourth large one with Novartis. If another partnership is announced in CHF, MSB irrespective of requiring more trials, could have a very prosperous future despite recent mitigated setbacks. We know the products have potential. They have been unlucky with the FDA in an unprecedented over-turn of a positive advisory vote and the application/design of two trials. Big Pharma will be looking at MSB very intently.

Expand

Spot on - all threads on MBS can be condensed into this statement of reality

MSB Price at posting: $2.47 Sentiment: Hold Disclosure: Held
10 Upvote

0 Great analysis

Reply

Top Stories

M4M

Macro, Norden set up transport solutions initiative for West Pilbara

SWP

Swoop lobs $18M offer at microcap telecom Vonex – in which it holds 19.9%

Week 42 Wrap: HotCopper's top picks; new ASX 200 record; world yawns at war

What's causing the cost-of-living crisis, and how to navigate it

NVU

Nanoveu surges 10% after benchmark testing for new AI chip begins

MKT

The ASX can overlook its Telecomm small-caps. Here’s one diversified brand with an international footprint

MTH

Mithril's drilling in Mexico picks up silver at 997g/t, gold at 28g/t

IRX

InhaleRX snags $38.5M in funding from VC biotech funder Clendon

TLG

Talga Group wins key permit for flagship graphite mine in Sweden

SNX

Sierra Nevada raises $2M for silver exploration at Blackhawk